| BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis SM Wilhelm, C Carter, LY Tang, D Wilkie, A McNabola, H Rong, C Chen, ... Cancer research 64 (19), 7099-7109, 2004 | 5289 | 2004 |
| Nivolumab for recurrent squamous-cell carcinoma of the head and neck RL Ferris, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ... New England Journal of Medicine 375 (19), 1856-1867, 2016 | 5036 | 2016 |
| Discovery and development of sorafenib: a multikinase inhibitor for treating cancer S Wilhelm, C Carter, M Lynch, T Lowinger, J Dumas, RA Smith, ... Nature reviews Drug discovery 5 (10), 835-844, 2006 | 2144 | 2006 |
| Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 L Liu, Y Cao, C Chen, X Zhang, A McNabola, D Wilkie, S Wilhelm, ... Cancer research 66 (24), 11851-11858, 2006 | 1844 | 2006 |
| Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling SM Wilhelm, L Adnane, P Newell, A Villanueva, JM Llovet, M Lynch Molecular cancer therapeutics 7 (10), 3129-3140, 2008 | 1715 | 2008 |
| Regorafenib (BAY 73‐4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity SM Wilhelm, J Dumas, L Adnane, M Lynch, CA Carter, G Schütz, ... International journal of cancer 129 (1), 245-255, 2011 | 1427 | 2011 |
| Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models YS Chang, J Adnane, PA Trail, J Levy, A Henderson, D Xue, E Bortolon, ... Cancer chemotherapy and pharmacology 59, 561-574, 2007 | 860 | 2007 |
| Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by … RL Ferris, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ... Oral oncology 81, 45-51, 2018 | 794 | 2018 |
| Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related … KJ Harrington, RL Ferris, G Blumenschein, AD Colevas, J Fayette, ... The Lancet Oncology 18 (8), 1104-1115, 2017 | 443 | 2017 |
| Biological characterization and oncogene expression in human colorectal carcinoma cell lines DL Trainer, T Kline, FL McCabe, LF Faucette, J Feild, M Chaikin, ... International journal of cancer 41 (2), 287-296, 1988 | 264 | 1988 |
| Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM A Jakubowiak, M Offidani, B Pégourie, J De La Rubia, L Garderet, K Laribi, ... Blood, The Journal of the American Society of Hematology 127 (23), 2833-2840, 2016 | 245 | 2016 |
| Antitumor activity of sorafenib in FLT3-driven leukemic cells D Auclair, D Miller, V Yatsula, W Pickett, C Carter, Y Chang, X Zhang, ... Leukemia 21 (3), 439-445, 2007 | 205 | 2007 |
| Nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: efficacy and safety in CheckMate 141 by prior cetuximab use RL Ferris, L Licitra, J Fayette, C Even, G Blumenschein Jr, KJ Harrington, ... Clinical Cancer Research 25 (17), 5221-5230, 2019 | 163 | 2019 |
| A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity SM Wilhelm, J Dumas, L Adnane, M Lynch, CA Carter, G Schütz, ... Int. J. Cancer 129 (1), 245-255, 2011 | 145 | 2011 |
| Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor WC Rose, FYF Lee, CR Fairchild, M Lynch, T Monticello, RA Kramer, ... Cancer research 61 (20), 7507-7517, 2001 | 141 | 2001 |
| A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of … N Kiyota, Y Hasegawa, S Takahashi, T Yokota, CJ Yen, S Iwae, Y Shimizu, ... Oral oncology 73, 138-146, 2017 | 118 | 2017 |
| Regulation by estrogen through the 5′-flanking region of the transforming growth factor α gene T Saeki, A Cristiano, MJ Lynch, M Brattain, N Kim, N Normanno, ... Molecular Endocrinology 5 (12), 1955-1963, 1991 | 107 | 1991 |
| CheckMate 141: 1‐year update and subgroup analysis of nivolumab as first‐line therapy in patients with recurrent/metastatic head and neck cancer ML Gillison, G Blumenschein Jr, J Fayette, J Guigay, AD Colevas, L Licitra, ... The oncologist 23 (9), 1079-1082, 2018 | 101 | 2018 |
| Ras farnesylation as a target for novel antitumor agents: potent and selective farnesyl diphosphate analog inhibitors of farnesyltransferase V Manne, CS Ricca, JG Brown, AV Tuomari, N Yan, D Patel, R Schmidt, ... Drug development research 34 (2), 121-137, 1995 | 100 | 1995 |
| Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation. JM Carboni, N Yan, AD Cox, X Bustelo, SM Graham, MJ Lynch, ... Oncogene 10 (10), 1905-1913, 1995 | 94 | 1995 |
